The Center for Global Health Policy’s “Science Speaks” blog reports on the status of two experimental drugs to treat tuberculosis. “On Friday, the European Medicines Agency issued a statement refusing authorization to market [the experimental drug] delamanid for treatment of drug-resistant tuberculosis, saying the benefits of delamanid ‘had not been sufficiently shown’ [in clinical trials] and ‘did not outweigh its risks,'” the blog notes. The Treatment Action Group (TAG) “responded to the agency’s decision with a statement calling it ‘myopic and deeply disappointing,'” the blog adds. “[E]arlier this month the Maryland-based pharmaceutical company Sequella announced that it had acquired rights to develop the lagging [experimental TB treatment] sutezolid from Pfizer, which had scaled back its work on drugs for infectious diseases,” the blog writes (Barton, 7/29).